| 1 |
34667024 | A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma. | 2022 Jan 1 |
2 |
| 2 |
33092063 | SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. | 2020 Oct 20 |
1 |
| 3 |
31402355 | Promoting antitumor efficacy by suppressing hypoxia via nano self-assembly of two irinotecan-based dual drug conjugates having a HIF-1α inhibitor. | 2019 Sep 11 |
2 |
| 4 |
29848680 | SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1α. | 2018 Jun |
7 |
| 5 |
29069732 | Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition. | 2017 Sep 22 |
1 |
| 6 |
24242862 | Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. | 2014 Apr |
2 |
| 7 |
25272957 | Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. | 2014 Oct 2 |
1 |
| 8 |
22033674 | In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. | 2012 Feb 10 |
3 |
| 9 |
22399605 | SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha. | 2012 Mar |
3 |
| 10 |
20066420 | Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. | 2010 Oct |
2 |
| 11 |
20066473 | Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. | 2010 Sep |
1 |
| 12 |
19190131 | Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. | 2009 Feb 15 |
3 |
| 13 |
20021826 | [Combination with SN-38 on human colon cancer LoVo cells]. | 2009 Oct |
3 |
| 14 |
16518418 | Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. | 2006 Apr 20 |
2 |
| 15 |
15583935 | Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. | 2005 Apr |
4 |